Skip to content
Biodatica
Start free

Genentech, Inc.

Tempe, Arizona

OncologyPhase IIIListed · RHHBY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

95no change

Momentum 95 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jun 30, 2026

    Early Breast Cancer · NOT_YET_RECRUITING · sponsor: Genentech, Inc. · A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

    ClinicalTrials.gov · NCT07541079 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jan 17, 2025

    Acute Kidney Injury · TERMINATED · sponsor: Genentech, Inc. · A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

    ClinicalTrials.gov · NCT06602453 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Oct 18, 2023

    Adenocarcinoma, Pancreatic Ductal · RECRUITING · sponsor: Genentech, Inc. · A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

    ClinicalTrials.gov · NCT05968326 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Oct 5, 2021

    Chronic Obstructive Pulmonary Disease · COMPLETED · sponsor: Genentech, Inc. · A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

    ClinicalTrials.gov · NCT05037929 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Aug 31, 2020

    Colorectal Cancer · COMPLETED · sponsor: Genentech, Inc. · A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

    ClinicalTrials.gov · NCT04468607 (opens the source filing in a new tab)

  6. Trial

    PHASE2 registered

    Aug 10, 2018

    Non-small Cell Lung Cancer · COMPLETED · sponsor: Genentech, Inc. · A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT03563716 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources